Search

Jan 15
SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, multiple myeloma, and lupus
She describes how the company's HLA matching and CD19 relapse testing is playing out, when we can expect to see new data, and how the...

Jun 3, 2024
Rachel Haurwitz on Caribou's #ASCO24 data and the rationale for taking time to look further at HLA matching for allo CAR-T
Rachel Haurwitz elaborates on the data update for CB-010 that was presented at ASCO and describes why the company will push back the...

Sep 6, 2023
Caribou Biosciences’ CEO on working toward a pivotal trial in 2nd line LBCL
Rachel Haurwitz describes recent data and the durability profile of Caribou’s allo CAR-T as the company plans to discuss a pivotal with FDA.

Jan 10, 2023
Rachel Haurwitz on allo CAR-T at #JPM23
Caribou Biosciences's CEO Rachel Haurwitz talks about her company's allogeneic CD19 CAR-T program that has a PD-1 knockout.